MX2022009170A - Procedimientos para el tratamiento del cancer con un anticuerpo antagonista anti-tigit. - Google Patents
Procedimientos para el tratamiento del cancer con un anticuerpo antagonista anti-tigit.Info
- Publication number
- MX2022009170A MX2022009170A MX2022009170A MX2022009170A MX2022009170A MX 2022009170 A MX2022009170 A MX 2022009170A MX 2022009170 A MX2022009170 A MX 2022009170A MX 2022009170 A MX2022009170 A MX 2022009170A MX 2022009170 A MX2022009170 A MX 2022009170A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- antagonist antibody
- tigit antagonist
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966448P | 2020-01-27 | 2020-01-27 | |
| US202062985822P | 2020-03-05 | 2020-03-05 | |
| US202062994272P | 2020-03-24 | 2020-03-24 | |
| PCT/US2020/024526 WO2021194481A1 (fr) | 2020-03-24 | 2020-03-24 | Dosage pour le traitement avec des anticorps antagonistes anti-tigit et anti-pd-l1 |
| US202063059054P | 2020-07-30 | 2020-07-30 | |
| US202063059960P | 2020-07-31 | 2020-07-31 | |
| US202063074807P | 2020-09-04 | 2020-09-04 | |
| US202063074827P | 2020-09-04 | 2020-09-04 | |
| PCT/US2020/049415 WO2022050954A1 (fr) | 2020-09-04 | 2020-09-04 | Dosage pour traitement avec anticorps antagonistes anti-tigit et anti-pd-l1 |
| US202063085890P | 2020-09-30 | 2020-09-30 | |
| US202063105198P | 2020-10-23 | 2020-10-23 | |
| US202063114517P | 2020-11-16 | 2020-11-16 | |
| US202063124693P | 2020-12-11 | 2020-12-11 | |
| US202063127109P | 2020-12-17 | 2020-12-17 | |
| PCT/US2021/015143 WO2021154761A1 (fr) | 2020-01-27 | 2021-01-26 | Méthodes de traitement du cancer au moyen d'un anticorps antagoniste anti-tigit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009170A true MX2022009170A (es) | 2022-08-17 |
Family
ID=74626264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009170A MX2022009170A (es) | 2020-01-27 | 2021-01-26 | Procedimientos para el tratamiento del cancer con un anticuerpo antagonista anti-tigit. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4096646A1 (fr) |
| JP (1) | JP2023511595A (fr) |
| KR (1) | KR20220133243A (fr) |
| CN (1) | CN115315256A (fr) |
| AU (1) | AU2021212662A1 (fr) |
| CA (1) | CA3165187A1 (fr) |
| IL (1) | IL294800A (fr) |
| MX (1) | MX2022009170A (fr) |
| TW (1) | TW202142230A (fr) |
| WO (1) | WO2021154761A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022015877A (es) * | 2020-06-16 | 2023-01-24 | Genentech Inc | Metodos y composiciones para tratar cancer de mama triple negativo. |
| CA3223534A1 (fr) * | 2021-07-02 | 2023-01-05 | Genentech, Inc. | Methodes et compositions pour le traitement du cancer |
| JP2024527049A (ja) * | 2021-07-28 | 2024-07-19 | ジェネンテック， インコーポレイテッド | がんを治療するための方法及び組成物 |
| WO2023018675A1 (fr) * | 2021-08-10 | 2023-02-16 | Merck Sharp & Dohme Llc | Méthodes de traitement du cancer, d'une maladie infectieuse ou d'une infection à l'aide d'une combinaison d'un antagoniste de tigit, d'un antagoniste de pd -1 et de lenvatinib ou d'un sel pharmaceutiquement acceptable de celui-ci |
| JP2024532744A (ja) * | 2021-08-10 | 2024-09-10 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｔ１ｇｉｔアンタゴニスト、ｐｄ－１アンタゴニスト、及び（１又は複数の）化学療法剤を含む治療的組合せ |
| WO2023040804A1 (fr) * | 2021-09-14 | 2023-03-23 | 信达生物制药(苏州)有限公司 | Composition pharmaceutique d'anticorps anti-pd-1 et agent chimiothérapeutique et son procédé d'utilisation |
| KR20240055080A (ko) * | 2021-09-15 | 2024-04-26 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Pd-1에 특이적으로 결합하는 단백질 및 그의 약학적 용도 |
| KR20240121771A (ko) * | 2021-12-22 | 2024-08-09 | 제넨테크, 인크. | 항-tigit 항체의 임상 제제 |
| CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
| WO2024130026A1 (fr) * | 2022-12-16 | 2024-06-20 | Elevar Therapeutics, Inc. | Méthodes et compositions pour le traitement de sujets présentant des troubles hépatiques |
| WO2024135809A1 (fr) * | 2022-12-23 | 2024-06-27 | 東レ株式会社 | Médicament pour le traitement et/ou la prévention du cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| WO1996003397A1 (fr) | 1994-07-21 | 1996-02-08 | Akzo Nobel N.V. | Formulations de peroxides cetoniques cycliques |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE122005000053I2 (de) | 1995-03-30 | 2008-01-17 | Pfizer Prod Inc | Chinazolinderivate |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| PT836605E (pt) | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| RO121900B1 (ro) | 1996-04-12 | 2008-07-30 | Warner-Lambert Company | Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| EP0980244B1 (fr) | 1997-05-06 | 2003-06-04 | Wyeth Holdings Corporation | Utilisation de composes de la quinazoline dans le traitement de la maladie polykystique des reins |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| KR20010031813A (ko) | 1997-11-06 | 2001-04-16 | 윌리암 에이취 캘넌, 에곤 이 버그 | 결장 폴립 치료용 티로신 키나제 억제제로서의 퀴나졸린유도체의 용도 |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| HUP0104211A3 (en) | 1998-11-19 | 2003-01-28 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it |
| EP3042964A1 (fr) | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Mutations egfr |
| EP2898329B1 (fr) | 2012-09-24 | 2017-05-17 | Ventana Medical Systems, Inc. | Méthode d'identification d'un cancer du poumon autre qu'à petites cellules (nsclc) réagissant à un traitement au moyen de la kinase du lymphome anaplasique (alk) comme marqueur |
| CN107667119A (zh) | 2015-05-12 | 2018-02-06 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
| EP4335931A3 (fr) | 2015-05-29 | 2024-06-19 | F. Hoffmann-La Roche AG | Méthodes thérapeutiques et diagnostiques du cancer |
| CN111836831A (zh) * | 2018-02-26 | 2020-10-27 | 豪夫迈·罗氏有限公司 | 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药 |
-
2021
- 2021-01-26 EP EP21705841.1A patent/EP4096646A1/fr active Pending
- 2021-01-26 CA CA3165187A patent/CA3165187A1/fr active Pending
- 2021-01-26 CN CN202180022830.2A patent/CN115315256A/zh active Pending
- 2021-01-26 JP JP2022545057A patent/JP2023511595A/ja active Pending
- 2021-01-26 AU AU2021212662A patent/AU2021212662A1/en active Pending
- 2021-01-26 WO PCT/US2021/015143 patent/WO2021154761A1/fr unknown
- 2021-01-26 MX MX2022009170A patent/MX2022009170A/es unknown
- 2021-01-26 TW TW110102913A patent/TW202142230A/zh unknown
- 2021-01-26 KR KR1020227029306A patent/KR20220133243A/ko unknown
- 2021-01-26 IL IL294800A patent/IL294800A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115315256A (zh) | 2022-11-08 |
| IL294800A (en) | 2022-09-01 |
| WO2021154761A1 (fr) | 2021-08-05 |
| JP2023511595A (ja) | 2023-03-20 |
| TW202142230A (zh) | 2021-11-16 |
| KR20220133243A (ko) | 2022-10-04 |
| AU2021212662A1 (en) | 2022-08-11 |
| CA3165187A1 (fr) | 2021-08-05 |
| EP4096646A1 (fr) | 2022-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009170A (es) | Procedimientos para el tratamiento del cancer con un anticuerpo antagonista anti-tigit. | |
| CY1120300T1 (el) | Αντισωματα ειδικα στην κλαουδινη 6 (cldn6) | |
| CY1117031T1 (el) | Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου | |
| ZA202110422B (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| MX2020012204A (es) | Inhibidores de kras g12c para tratar el cáncer. | |
| MX2019009967A (es) | Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas. | |
| JOP20170131B1 (ar) | مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان | |
| CA3156451A1 (fr) | Anticorps ayant une specificite pour la nectine -4 et leurs utilisations | |
| MY163024A (en) | Therapy of platinum-resistan cancer | |
| MY152864A (en) | Treatment of metastatic breast cancer | |
| MX2020011779A (es) | Anticuerpos para el tratamiento del cancer. | |
| NZ607337A (en) | Antibodies for epidermal growth factor receptor 3 (her3) | |
| WO2021007428A3 (fr) | Molécules, compositions et méthodes de traitement du cancer | |
| EA024630B9 (ru) | Производные пиразола как ингибиторы ионных каналов, активируемых высвобождением кальция (crac) | |
| NZ628298A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| MX2009009816A (es) | Anticuerpos monoclonales para el tratamiento del cancer. | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| MX2020008613A (es) | Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer. | |
| RU2016112421A (ru) | Протиоопухолевое средство и усилитель противоопухолевого эффекта | |
| PE20221830A1 (es) | Anticuerpos especificos contra la claudina 18.2 tumoral | |
| MX2024002238A (es) | Anticuerpos anti-ccr8 y uso de los mismos. | |
| MX2024005343A (es) | Derivados de quinazolina tetraciclicos fusionados como inhibidores de erbb2. | |
| MY188446A (en) | Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr) | |
| MX2021005784A (es) | Compuestos que inhiben de manera selectiva y efectiva la biquitinación mediada por hakai, como fármacos anti-cáncer. | |
| MX2021012644A (es) | Integrina alfa 10 y formas de cancer agresivo. |